Prana launches Phase II study of Alzheimer's drug

03/6/2012 | ProactiveInvestors.co.au (Australia)

Prana Biotechnology has started with the first patient in a 12-month Phase II trial that will monitor levels of amyloid in the brain and assess cognitive and functional abilities in participants treated with PBT2, the company's investigational drug for Alzheimer's disease. Study participants will undergo PiB-PET imaging prior to treatment to determine starting amyloid levels.

View Full Article in:

ProactiveInvestors.co.au (Australia)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations